Lilly Weight-Loss Drug Data Spurs Selloff in Sleep Apnea Stocks Yahoo FinanceLilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution | Eli Lilly and Company Investors | Eli Lilly and CompanyAmid duel with Novo's Wegovy, Lilly's Zepbound homes in on potential FDA sleep apnea nod FiercePharmaWeight-Loss Drug Zepbound Offers a New Way to Treat Sleep Apnea The New York Times